Bibloc(BisoHEXAL 1.25 mg Film-coated Tablets)
Bisoprolol fumarate
Bibloc and BisoHEXAL 1.25 mg Film-coated Tablets are different trade names for the same medicine.
Bibloc belongs to a group of medicines called beta-blockers. They protect the heart from excessive activity.
Bibloc is used to treat:
If you have any doubts, you should consult your doctor.
Before starting to take Bibloc, you should consult your doctor:
So far, there is no therapeutic experience with the use of Bibloc in heart failure in the following patients:
Treatment of heart failure with Bibloc requires systematic medical monitoring. This is absolutely necessary, especially at the beginning of treatment and after its completion.
Do not stop taking Bibloc suddenly without a compelling reason.
If any of the described warnings apply to you or have applied in the past, you should consult your doctor or pharmacist.
You should tell your doctor or pharmacist about all the medicines you are currently taking or have recently taken, as well as any medicines you plan to take. This also applies to medicines that are available without a prescription. Certain medicines should not be taken at the same time as Bibloc, and others may require changes, such as dose.
In each case, you should inform your doctor about taking or receiving, in addition to Bibloc, the following medicines:
Alcohol may increase the dizziness and drowsiness caused by Bibloc. In this case, you should avoid drinking alcohol.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor before taking this medicine. Bibloc may have a harmful effect on the course of pregnancy and (or) the fetus. The risk of premature birth, miscarriage, low blood sugar in the child, and slowing of the child's heart rate increases. The medicine may also affect the development of the child. Therefore, Bibloc should not be taken during pregnancy.
It is not known whether bisoprolol passes into breast milk, so it is not recommended to take Bibloc while breastfeeding.
The medicine may cause fatigue, drowsiness, or dizziness. If these symptoms occur, you should not drive vehicles or operate machines. You should be aware that such symptoms may occur, especially at the beginning of treatment, when changing the medicine, and when consuming alcohol.
If you have previously been diagnosed with intolerance to some sugars, you should contact your doctor before taking the medicine.
This medicine contains less than 1 mmol (23 mg) of sodium per film-coated tablet, which means the medicine is considered "sodium-free".
This medicine should always be taken according to the doctor's or pharmacist's instructions. If you have any doubts, you should consult your doctor or pharmacist.
Your doctor will inform you how many tablets to take. The medicine should be taken in the morning, before, during, or after breakfast. The tablet (tablets) should be swallowed with a small amount of water. The tablets should not be chewed or crushed.
The usual dose is:
Before starting to take Bibloc, you are usually already taking an ACE inhibitor, diuretic, or digitalis glycoside (a heart medicine and antihypertensive).
The dose of the medicine will be gradually increased until the optimal dose for you is reached:
1.25 mg once a day for 1 week. If this dose is well tolerated, it can be increased to:
2.5 mg once a day for the next week. If this dose is well tolerated, it can be increased to:
3.75 mg once a day for the next week. If this dose is well tolerated, it can be increased to:
5 mg once a day for 4 consecutive weeks. If this dose is well tolerated, it can be increased to:
7.5 mg once a day for 4 consecutive weeks. If this dose is well tolerated, it can be increased to:
10 mg once a day (maintenance dose).
The maximum dose is 10 mg once a day.
Your doctor will determine the optimal dose for you based on, among other things, side effects.
After the first dose of 1.25 mg, your doctor will check your blood pressure, heart rate, and heart function.
In the case of liver or kidney function disorders, your doctor will carefully increase the dose of the medicine.
In the elderly, dose adjustment is not usually necessary.
If you feel that the effect of Bibloc is too strong or too weak, you should inform your doctor or pharmacist.
Duration of treatment
Bibloc is usually taken for a long time.
Due to the lack of studies on the effect of Bibloc in children and adolescents, its use is not recommended in this age group.
In case of accidental ingestion of a higher dose than recommended, you should immediately contact
your doctor or pharmacist. You should take the remaining tablets or this leaflet with you, so that the medical staff knows what medicine has been taken. Symptoms of overdose may include dizziness, drowsiness, fatigue, shortness of breath and (or) wheezing. Slow heart rate, low blood pressure, inadequate heart contraction force, and low blood sugar (which can cause hunger, excessive sweating, and palpitations) may also occur.
You should not take a double dose to make up for a missed dose. You should take the usual dose as soon as you remember, and the next day return to the normal dosing schedule.
You should not stop taking Bibloc suddenly. If treatment is stopped suddenly, the disease may worsen. The dose of the medicine should be gradually reduced over several weeks, according to your doctor's instructions.
If you have any further doubts about taking this medicine, you should consult your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If a side effect is serious, occurs suddenly, or worsens rapidly, you should immediately contact your doctor to prevent severe reactions.
The most serious side effects are related to heart function:
If you experience dizziness, weakness, or difficulty breathing, you should contact your doctor as soon as possible.
If you experience severe hypersensitivity reactions, which may include swelling of the face, neck, tongue, lips, or throat, or difficulty breathing, you should immediately contact your doctor.
The following side effects are listed below by frequency of occurrence:
Common (may occur less frequently than in 1 in 10 people):
Uncommon (may occur less frequently than in 1 in 100 people):
Rare (may occur less frequently than in 1 in 1,000 people):
Very rare (may occur less frequently than in 1 in 10,000 people):
If you experience any side effects, including those not listed in this leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, you can help gather more information on the safety of the medicine.
The medicine should be stored in a place that is out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Translation of some information on the immediate packaging:
Ch.-B./verwendbar bis: siehe Prägung– batch number/expiry date: see imprint.
There are no special precautions for storage.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
White, round, film-coated tablets marked "BIS 1.25" on one side.
The tablets are packaged in OPA/Aluminum/PVC/Aluminum blisters in a cardboard box.
The blisters contain 25 or 50 tablets.
To obtain more detailed information, you should contact the marketing authorization holder or parallel importer.
Hexal AG
Industriestraße 25
83607 Holzkirchen, Germany
Lek S.A., ul. Podlipie 16, Stryków 95-010, Poland
Salutas Pharma GmbH, Otto-von-Guericke-Allee 1, 39179 Barleben, Germany
Rowa Pharmaceuticals Limited, Newtown, Bantry, Co. Cork, Ireland
Lek Pharmaceuticals d.d, Verovskova ulica 57, 1526 Ljubljana, Slovenia
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Authorization number in Germany, the country of export:71878.00.00
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.